Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join

Virtual Event

Sep 28, 2020 2:00 PM - Sep 30, 2020 6:00 PM

(Central Europe Standard Time)

4051 Basel, Switzerland

Regulatory Science Forum

Session 1: Setting the scene - Why is Regulatory Science research important?

Session Chair(s)

Sini  Eskola, MPharm, MS, MSc

Sini Eskola, MPharm, MS, MSc

Director Regulatory Affairs

EFPIA - European Federation of Pharmaceutical Industries and Associations, Belgium

Regulatory Science is a field looking into developing new tools, standards and approaches to evaluate the efficacy, safety, quality and performance of medicines in order to assess their benefit-risk balance and facilitate a sound and transparent regulatory decision-making. It is the basis for the pharmaceutical regulation to evolve. It can be a fast-moving and exciting research area where for example advances in data analytics, ability to collect the real-world data and turn it into the real-world evidence to support regulatory decision making and rapidly advancing science are transforming the way new treatments are developed. To remain competitive, all regions have to continue to evolve their respective regulatory system to remain at the cutting edge of regulatory science and policy. It also requires collaboration between the regulators, academia, industry and patients. This session explores examples on what major regions and stakeholders are doing to advance their priority topics in regulatory science research and how that contributes to policy making and current practices/regulation.

Speaker(s)

Tony  Humphreys, MPharm

EMA Regulatory Science Strategy 2025

Tony Humphreys, MPharm

European Medicines Agency, Netherlands

Head of the Regulatory Science and Innovation Task Force

Tony  Humphreys, MPharm

Panel discussion with Q&A, with the participation of:

Tony Humphreys, MPharm

European Medicines Agency, Netherlands

Head of the Regulatory Science and Innovation Task Force

Gerald  Dal Pan, MD, MHS

Panel discussion with Q&A, with the participation of:

Gerald Dal Pan, MD, MHS

FDA, United States

Director, Office of Surveillance and Epidemiology, CDER

Hubert  Leufkens, PharmD, PhD

Panel discussion with Q&A, with the participation of:

Hubert Leufkens, PharmD, PhD

Utrecht University, Netherlands

Emeritus Professor of Pharmaceutical Policy and Regulatory Science

Susan  Longman

Panel discussion with Q&A, with the participation of:

Susan Longman

Novartis Pharma AG, Switzerland

Head Regulatory Affairs Region Europe

Have an account?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.